Salud financiera de hoja de balance de Changmao Biochemical Engineering

Salud financiera controles de criterios 3/6

Changmao Biochemical Engineering tiene un patrimonio de accionistas total de CN¥651.6M y una deuda total de CN¥492.6M, lo que sitúa su ratio deuda-patrimonio en 75.6%. Sus activos y pasivos totales son CN¥1.2B y CN¥590.9M respectivamente. El BAIT de Changmao Biochemical Engineering es de CN¥21.6M, por lo que su ratio de cobertura de intereses es de 3.3. Tiene efectivo e inversiones a corto plazo que ascienden a CN¥96.6M.

Información clave

75.6%

Ratio deuda-patrimonio

CN¥492.61m

Deuda

Ratio de cobertura de intereses	3.3x
Efectivo	CN¥96.56m
Patrimonio	CN¥651.59m
Total pasivo	CN¥590.91m
Activos totales	CN¥1.24b

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Investors Will Want Changmao Biochemical Engineering's (HKG:954) Growth In ROCE To Persist

Aug 02

Returns On Capital At Changmao Biochemical Engineering (HKG:954) Have Stalled

Nov 18

We Believe Changmao Biochemical Engineering's (HKG:954) Earnings Are A Poor Guide For Its Profitability

Apr 28

Changmao Biochemical Engineering (HKG:954) Will Be Looking To Turn Around Its Returns

Aug 03

Changmao Biochemical Engineering (HKG:954) May Have Issues Allocating Its Capital

May 04

Tread With Caution Around Changmao Biochemical Engineering Company Limited's (HKG:954) 8.8% Dividend Yield

Feb 23

Will Changmao Biochemical Engineering (HKG:954) Multiply In Value Going Forward?

Jan 26

A Quick Analysis On Changmao Biochemical Engineering's (HKG:954) CEO Salary

Dec 02

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (CN¥338.3M) de 954 superan a sus pasivos a corto plazo (CN¥325.2M).

Pasivo a largo plazo: Los activos a corto plazo de 954 (CN¥338.3M) superan a sus pasivos a largo plazo (CN¥265.7M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: La relación deuda neta-capital de 954 (60.8%) se considera alta.

Reducción de la deuda: El ratio deuda-patrimonio de 954 ha crecido de 6.2% a 75.6% en los últimos 5 años.

Cobertura de la deuda: El flujo de caja operativo de 954 es negativo, por lo que la deuda no está bien cubierta.

Cobertura de intereses: Los pagos de intereses de la deuda de 954 están bien cubiertos por el BAIT (3.3x cobertura).

Salud financiera de hoja de balance de Changmao Biochemical Engineering

Salud financiera controles de criterios 3/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Chairman & Compliance Officer recently bought HK$836k worth of stock

Chairman & Compliance Officer recently bought HK$164k worth of stock

Changmao Biochemical Engineering Company Limited, Annual General Meeting, May 28, 2024

Full year 2023 earnings released: CN¥0.16 loss per share (vs CN¥0.15 profit in FY 2022)

New minor risk - Financial data availability

Changmao Biochemical Engineering Company Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Chairman & Compliance Officer recently bought HK$59k worth of stock

Chairman & Compliance Officer recently bought HK$231k worth of stock

Chairman & Compliance Officer recently bought HK$54k worth of stock

Chairman & Compliance Officer recently bought HK$327k worth of stock

Chairman & Compliance Officer recently bought HK$277k worth of stock

New major risk - Financial position

First half 2023 earnings released: EPS: CN¥0.008 (vs CN¥0.077 in 1H 2022)

Changmao Biochemical Engineering Company Limited to Report First Half, 2023 Results on Aug 18, 2023

Investors Will Want Changmao Biochemical Engineering's (HKG:954) Growth In ROCE To Persist

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

Changmao Biochemical Engineering Company Limited approves Final Dividend for the Year Ended 31 December 2022, Payable on 18 July 2023

Upcoming dividend of CN¥0.077 per share at 8.4% yield

Full year 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.11 in FY 2021)

Returns On Capital At Changmao Biochemical Engineering (HKG:954) Have Stalled

Less than half of directors are independent

First half 2022 earnings released: EPS: CN¥0.077 (vs CN¥0 in 1H 2021)

Changmao Biochemical Engineering Company Limited Announces Appointment of Ms. Cheng Mun Wah as Independent Non-Executive Director and Chairman of Audit Committee, and Member of Remuneration Committee and Nomination Committee

First half 2022 earnings released: EPS: CN¥0 (vs CN¥0 in 1H 2021)

Changmao Biochemical Engineering Company Limited to Report First Half, 2022 Results on Aug 18, 2022

Changmao Biochemical Engineering Company Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2022

Changmao Biochemical Engineering Company Limited Appoints Cheng Mun Wah as Independent Non-Executive Director and Chairman of Audit Committee and Member of Remuneration Committee and Nomination Committee

Changmao Biochemical Engineering Company Limited Approves Board Resignations, Effective 18 June 2022

We Believe Changmao Biochemical Engineering's (HKG:954) Earnings Are A Poor Guide For Its Profitability

Less than half of directors are independent

Changmao Biochemical Engineering Company Limited Omits Final Dividend for the Year Ended 31 December 2021

Full year 2021 earnings released

Changmao Biochemical Engineering (HKG:954) Will Be Looking To Turn Around Its Returns

Upcoming dividend of CN¥0.02 per share

Changmao Biochemical Engineering (HKG:954) May Have Issues Allocating Its Capital

Full year 2020 earnings released: EPS CN¥0.032 (vs CN¥0.11 in FY 2019)

Full year 2020 earnings released

Changmao Biochemical Engineering Company Limited Provides Earnings Guidance for the Year Ended 31 December 2020

Changmao Biochemical Engineering Company Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

Tread With Caution Around Changmao Biochemical Engineering Company Limited's (HKG:954) 8.8% Dividend Yield

Will Changmao Biochemical Engineering (HKG:954) Multiply In Value Going Forward?

New 90-day high: HK$0.65

A Quick Analysis On Changmao Biochemical Engineering's (HKG:954) CEO Salary

New 90-day low: HK$0.56

First half earnings released

New 90-day low - HK$0.59

First half earnings released

Changmao Biochemical Engineering Company Limited to Report First Half, 2020 Results on Aug 28, 2020

New 90-day low - HK$0.60

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Descubre empresas con salud financiera